Profile data is unavailable for this security.
About the company
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
- Revenue in USD (TTM)2.65m
- Net income in USD-86.46m
- Incorporated2018
- Employees70.00
- LocationAligos Therapeutics IncOne Corporate Dr., 2nd Floor, 2nd FloorSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://www.aligos.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tvardi Therapeutics Inc | 4.02m | -13.95m | 37.15m | 10.00 | -- | 1.33 | -- | 9.23 | -8.36 | -8.36 | 0.7709 | 2.97 | 0.0891 | -- | -- | 402,400.00 | -30.87 | -36.79 | -40.26 | -41.45 | 100.00 | -- | -346.55 | -155.60 | -- | -- | 0.00 | -- | -65.96 | -18.53 | 40.20 | -- | 125.35 | -- |
| Sensei Biotherapeutics Inc | 0.00 | -24.14m | 37.60m | 14.00 | -- | 1.63 | -- | -- | -19.16 | -19.16 | 0.00 | 18.24 | 0.00 | -- | -- | 0.00 | -59.72 | -43.45 | -68.03 | -48.13 | -- | -- | -- | -- | -- | -- | 0.0083 | -- | -- | -- | 11.57 | -- | 22.47 | -- |
| Jasper Therapeutics Inc | 0.00 | -91.02m | 37.78m | 64.00 | -- | 3.26 | -- | -- | -5.90 | -5.90 | 0.00 | 0.4135 | 0.00 | -- | -- | 0.00 | -116.04 | -75.11 | -147.54 | -86.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.55 | -- | -- | -- |
| ABVC Biopharma Inc | 797.92k | -4.12m | 38.19m | 16.00 | -- | 2.97 | -- | 47.86 | -0.2223 | -0.2223 | 0.0464 | 0.4985 | 0.0448 | -- | 0.408 | 49,870.00 | -24.89 | -105.17 | -42.73 | -217.00 | 0.2469 | 75.19 | -555.90 | -2,124.21 | 0.6241 | -13.71 | 0.0662 | -- | 234.31 | -6.20 | 37.05 | -- | -- | -- |
| Onkure Therapeutics Inc | 0.00 | -81.21m | 38.34m | 46.00 | -- | 0.5772 | -- | -- | -12.78 | -12.78 | 0.00 | 4.90 | 0.00 | -- | -- | 0.00 | -107.93 | -48.73 | -115.20 | -53.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 31.94 | -- | 49.34 | -- |
| Lisata Therapeutics Inc | 1.07m | -18.24m | 38.63m | 26.00 | -- | 2.21 | -- | 36.11 | -2.13 | -2.13 | 0.1246 | 1.98 | 0.0357 | -- | -- | 41,153.85 | -60.85 | -44.77 | -71.25 | -49.07 | -- | -- | -1,704.86 | -13,065.70 | -- | -- | 0.00 | -- | -- | -- | 4.10 | -- | -- | -- |
| Atossa Therapeutics Inc | 0.00 | -30.18m | 38.75m | 13.00 | -- | 0.7783 | -- | -- | -3.52 | -3.52 | 0.00 | 5.78 | 0.00 | -- | -- | 0.00 | -43.90 | -26.93 | -48.89 | -29.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 15.25 | -- | 20.02 | -- |
| Palatin Technologies Inc | 8.96m | -9.63m | 39.79m | 29.00 | -- | 3.44 | -- | 4.44 | -10.46 | -10.46 | 7.19 | 6.53 | 0.8062 | -- | -- | 309,089.30 | -86.59 | -79.95 | -303.40 | -118.70 | 0.00 | 91.70 | -107.41 | -1,326.05 | -- | -- | 0.00 | -- | -100.00 | -- | 41.80 | -- | -- | -- |
| Impact Biomedical Inc | 25.00k | -44.19m | 41.93m | 2.00 | -- | -- | -- | 1,677.29 | -3.76 | -3.76 | 0.0021 | -0.9691 | 0.0008 | -- | 3.33 | 12,500.00 | -136.32 | -18.99 | -260.12 | -26.29 | 52.00 | -- | -176,952.00 | -78,189.58 | 0.0182 | -0.2682 | 1.63 | -- | -- | -- | -469.83 | -- | -- | -- |
| Veru Inc | 0.00 | -19.20m | 42.05m | 20.00 | -- | 1.13 | -- | -- | -1.21 | -1.20 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -43.95 | -47.51 | -51.96 | -59.79 | -- | -- | -- | -188.81 | -- | -- | 0.00 | -- | -- | -- | 55.53 | -- | -60.02 | -- |
| Aligos Therapeutics Inc | 2.65m | -86.46m | 42.86m | 70.00 | -- | 0.5967 | -- | 16.20 | -12.70 | -12.70 | 0.2964 | 11.67 | 0.0267 | -- | -- | 37,800.00 | -87.25 | -60.83 | -111.39 | -72.31 | -- | -- | -3,267.65 | -1,462.14 | -- | -- | 0.002 | -- | -74.60 | -- | -49.65 | -- | -45.83 | -- |
| Incannex Healthcare Inc | 0.00 | -48.50m | 45.63m | 12.00 | -- | 0.623 | -- | -- | -18.65 | -18.65 | 0.00 | 6.13 | 0.00 | -- | -- | 0.00 | -112.64 | -155.80 | -123.21 | -186.20 | -- | -- | -- | -6,230.96 | -- | -280.00 | 0.00 | -- | 616.67 | -31.02 | -154.00 | -- | -- | -- |
| Klotho Neurosciences Inc | 0.00 | -11.29m | 47.48m | 3.00 | -- | 4.57 | -- | -- | -0.3264 | -0.3264 | 0.00 | 0.1411 | 0.00 | -- | -- | 0.00 | -180.10 | -- | -197.00 | -- | -- | -- | -- | -- | -- | -1.90 | 0.00 | -- | -- | -- | -556.89 | -- | -- | -- |
| Estrella Immunopharma Inc | 0.00 | -13.50m | 47.92m | -- | -- | -- | -- | -- | -0.3697 | -0.3697 | 0.00 | -0.2605 | 0.00 | -- | -- | -- | -371.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Acrivon Therapeutics Inc | 0.00 | -81.75m | 48.28m | 75.00 | -- | 0.3754 | -- | -- | -2.13 | -2.13 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -45.42 | -- | -49.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.40 | -- | -- | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.35m | 48.56m | 2.00 | -- | -- | -- | -- | -0.0396 | -0.0396 | 0.00 | -0.0817 | 0.00 | -- | -- | 0.00 | -904.16 | -- | -- | -- | -- | -- | -- | -- | -- | -7.46 | -- | -- | -- | -- | -19.61 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Aligos Therapeutics Inc's reporting currency: US Dollar USD
43.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Deep Track Capital LPas of 31 Dec 2025 | 444.11k | 8.30% |
| Alyeska Investment Group LPas of 31 Dec 2025 | 412.00k | 7.70% |
| Sio Capital Management LLCas of 31 Dec 2025 | 335.94k | 6.28% |
| Woodline Partners LPas of 31 Dec 2025 | 289.17k | 5.40% |
| Marshall Wace LLPas of 31 Dec 2025 | 268.66k | 5.02% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 171.02k | 3.20% |
| Summittx Capital LPas of 31 Dec 2025 | 139.42k | 2.60% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 85.44k | 1.60% |
| Baker Bros. Advisors LPas of 31 Dec 2025 | 83.06k | 1.55% |
| Two Sigma Investments LPas of 31 Dec 2025 | 80.65k | 1.51% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
